Unlocking the Blockbuster Potential of
Adora's Revolutionizing Osteoarthritis Treatment
Adora Life Science is pioneering a new era in osteoarthritis treatment with its innovative and patented PSGAG technology platform, targeting the multi billion dollar market opportunity with a first in class disease modifying drug.
Mission Statement
Adora is laser focused on unlocking the potential of our patented PSGAG technology by developing and commercializing dosage forms of this disease modifying antiarthritic veterinary product for the human market.
Highlights
Human-Focused Innovation
Developing the first topical disease modifying drug for osteoarthritis.
Massive Market Opportunity
Addressing an $8B+ global osteoarthritis market opportunity.
Strong IP Protection
Patent exclusivity through Q3 2043.
Experienced Team
Led by biotech executives with $2B+ exits and global commercialization expertise.
A, Normal: smooth surface, heavy red stain of proteoglycans, no increase or decrease in chondrocytes and one well-defined tidemark. B, Osteoarthritis: disrupted cartilage surface, proliferation of chondrocytes with many pyknotic chondrocytes (indicating cell death), sparse red stain of proteoglycans that is only present around chondrocytes, and duplicated tidemark invaded by blood vessels.
Our Affiliations
